BioVaxys Technology Corp. (CSE:BIOV)
Canada flag Canada · Delayed Price · Currency is CAD
0.0400
0.00 (0.00%)
Apr 25, 2025, 3:59 PM EDT

BioVaxys Technology Cash Flow Statement

Millions CAD. Fiscal year is Nov - Oct.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019
Period Ending
Jan '25 Oct '24 Oct '23 Oct '22 Oct '21 Oct '20 2019
Net Income
-5.54-3.95-7.69-11.73-6.46-1.17
Upgrade
Asset Writedown & Restructuring Costs
1.291.291.457.4--
Upgrade
Stock-Based Compensation
0.350.33.250.621.250.35
Upgrade
Other Operating Activities
1.150.45-0.250.23-00.07
Upgrade
Change in Accounts Payable
0.220.691.81.98-0.50.18
Upgrade
Change in Other Net Operating Assets
-0.22-0.640.39-0.070.42-0.63
Upgrade
Operating Cash Flow
-2.76-1.86-1.05-1.57-5.29-1.23
Upgrade
Cash Acquisitions
-----0.04
Upgrade
Sale (Purchase) of Intangibles
-1.06-1.06----
Upgrade
Other Investing Activities
-----0.02
Upgrade
Investing Cash Flow
-1.06-1.06---0.06
Upgrade
Short-Term Debt Repaid
--0.03----
Upgrade
Total Debt Repaid
-0.03-0.03----
Upgrade
Net Debt Issued (Repaid)
-0.03-0.03----
Upgrade
Issuance of Common Stock
3.043.160.921.133.783.33
Upgrade
Other Financing Activities
----0.03-0.340.02
Upgrade
Financing Cash Flow
3.013.130.921.113.443.35
Upgrade
Foreign Exchange Rate Adjustments
-0.010-00.020.030.01
Upgrade
Net Cash Flow
-0.810.21-0.14-0.45-1.832.19
Upgrade
Levered Free Cash Flow
-3.59-4.014.06-0.74-2.71-0.06
Upgrade
Unlevered Free Cash Flow
-3.59-4.014.06-0.74-2.71-0.06
Upgrade
Change in Net Working Capital
0.431.31-2.31-1.020.22-0.22
Upgrade
Updated Mar 19, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.